S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Stock market today: Wall Street drifts higher, marking 4th winning week for S&P 500
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Why Turkey's currency is crashing after Erdogan got reelected
Even at $2,000+ Per Share, These 3 Stocks Are Deals
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Stock market today: Wall Street drifts higher, marking 4th winning week for S&P 500
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Why Turkey's currency is crashing after Erdogan got reelected
Even at $2,000+ Per Share, These 3 Stocks Are Deals
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Stock market today: Wall Street drifts higher, marking 4th winning week for S&P 500
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Why Turkey's currency is crashing after Erdogan got reelected
Even at $2,000+ Per Share, These 3 Stocks Are Deals
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Stock market today: Wall Street drifts higher, marking 4th winning week for S&P 500
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Why Turkey's currency is crashing after Erdogan got reelected
Even at $2,000+ Per Share, These 3 Stocks Are Deals
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
NASDAQ:EYE

National Vision (EYE) Competitors

$26.08
-0.67 (-2.50%)
(As of 06/9/2023 ET)
Compare
Today's Range
$25.97
$26.95
50-Day Range
$18.54
$26.75
52-Week Range
$17.25
$43.82
Volume
848,501 shs
Average Volume
1.34 million shs
Market Capitalization
$2.04 billion
P/E Ratio
70.49
Dividend Yield
N/A
Price Target
$30.33

EYE vs. STAA, WRBY, BLCO, VTYX, NUVA, ABCL, NEO, ACLX, AMEH, and HIMS

Should you be buying National Vision stock or one of its competitors? The main competitors of National Vision include STAAR Surgical (STAA), Warby Parker (WRBY), Bausch + Lomb (BLCO), Ventyx Biosciences (VTYX), NuVasive (NUVA), AbCellera Biologics (ABCL), NeoGenomics (NEO), Arcellx (ACLX), Apollo Medical (AMEH), and Hims & Hers Health (HIMS). These companies are all part of the "medical" sector.

National Vision vs.

National Vision (NASDAQ:EYE) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability.

STAAR Surgical has a net margin of 10.81% compared to National Vision's net margin of 1.48%. STAAR Surgical's return on equity of 9.85% beat National Vision's return on equity.

Company Net Margins Return on Equity Return on Assets
National Vision 1.48% 3.99% 1.56%
STAAR Surgical 10.81% 9.85% 7.93%

97.6% of STAAR Surgical shares are held by institutional investors. 2.1% of National Vision shares are held by company insiders. Comparatively, 1.1% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

National Vision has higher revenue and earnings than STAAR Surgical. National Vision is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Vision$2.01 billion1.02$42.12 million$0.3770.49
STAAR Surgical$294.72 million8.40$38.76 million$0.6480.02

National Vision has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

STAAR Surgical received 22 more outperform votes than National Vision when rated by MarketBeat users. However, 67.65% of users gave National Vision an outperform vote while only 58.51% of users gave STAAR Surgical an outperform vote.

CompanyUnderperformOutperform
National VisionOutperform Votes
253
67.65%
Underperform Votes
121
32.35%
STAAR SurgicalOutperform Votes
275
58.51%
Underperform Votes
195
41.49%

National Vision presently has a consensus target price of $30.33, suggesting a potential upside of 16.31%. STAAR Surgical has a consensus target price of $81.18, suggesting a potential upside of 58.53%. Given STAAR Surgical's higher possible upside, analysts plainly believe STAAR Surgical is more favorable than National Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Vision
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
STAAR Surgical
0 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, STAAR Surgical had 3 more articles in the media than National Vision. MarketBeat recorded 12 mentions for STAAR Surgical and 9 mentions for National Vision. National Vision's average media sentiment score of 0.63 beat STAAR Surgical's score of 0.46 indicating that National Vision is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
National Vision
3 Very Positive mention(s)
5 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
STAAR Surgical
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

STAAR Surgical beats National Vision on 11 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EYE vs. The Competition

MetricNational VisionOphthalmic goods IndustryMedical SectorNASDAQ Exchange
Market Cap$2.04B$10.68B$4.59B$6.28B
Dividend YieldN/A0.83%2.27%6.20%
P/E Ratio70.4958.46128.0314.98
Price / Sales1.027.533,401.6099.51
Price / Cash14.2921.8992.48113.59
Price / Book2.283.824.705.30
Net Income$42.12M$199.84M$118.08M$193.23M
7 Day Performance0.42%-1.76%0.88%1.57%
1 Month Performance14.74%-1.76%1.06%4.63%
1 Year Performance-1.99%10.02%18.92%5.87%

National Vision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAA
STAAR Surgical
2.6337 of 5 stars
$54.79
-2.9%
$81.18
+48.2%
-26.6%$2.65B$284.39M85.61692Analyst Downgrade
News Coverage
Positive News
High Trading Volume
WRBY
Warby Parker
0.9161 of 5 stars
$12.08
+0.3%
$16.82
+39.2%
-24.2%$1.16B$598.11M-15.893,032Insider Selling
Positive News
BLCO
Bausch + Lomb
1.2899 of 5 stars
$18.44
+0.1%
$19.44
+5.5%
+26.8%$6.46B$3.77B-61.4512,900Positive News
High Trading Volume
VTYX
Ventyx Biosciences
1.8532 of 5 stars
$34.80
+1.5%
$55.40
+59.2%
+100.8%$2.03BN/A-15.2627Insider Selling
News Coverage
NUVA
NuVasive
2.1818 of 5 stars
$39.65
+1.7%
$50.98
+28.6%
-24.6%$2.08B$1.20B116.623,000Analyst Report
ABCL
AbCellera Biologics
1.9355 of 5 stars
$6.91
+1.2%
$25.57
+270.1%
-15.5%$2.00B$485.42M-38.39386News Coverage
NEO
NeoGenomics
1.453 of 5 stars
$16.60
+0.1%
$19.55
+17.7%
+103.2%$2.12B$509.73M-16.442,100
ACLX
Arcellx
2.0464 of 5 stars
$41.02
+0.0%
$50.38
+22.8%
+91.2%$1.97BN/A-9.4578
AMEH
Apollo Medical
2.3554 of 5 stars
$33.59
+3.5%
$53.67
+59.8%
-8.5%$1.93B$1.14B31.691,362
HIMS
Hims & Hers Health
2.0649 of 5 stars
$9.20
+2.8%
$11.91
+29.5%
+129.5%$1.92B$526.92M-31.71398Insider Selling

Related Companies and Tools

This page (NASDAQ:EYE) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -